Some have relabeled it as Pentadecapeptide Aringate or PDA (modifying the acetate to an arginate) and are prescribing it for subcutaneous administration this way, when the confusion about its status has triggered a vivid oral capsule market for BPC in what appears to generally be a gray location of legality. https://perrya333ask4.scrappingwiki.com/user